CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
SYDNEY, Australia, April 12, 2018 -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April 2018. The Company received applications from eligible shareholders for 300,561,089 new ordinary shares (“New Shares”) at the purchase price of $0.021 per New Share.
Accordingly, the Company has raised A$6.31 million before transaction-related expenses through the SPP. This is in addition to A$6.85 million institutional placement announced on 12 March 2018, bringing the total funds raised from the SPP and institutional placement to A$ 13.16 million.
The funds raised from the SPP and Placement will be used to support Immutep’s ongoing and planned immuno-oncology clinical development programs, its pre-clinical program in autoimmune disease and for general working capital purposes.
“It is great to see so many of our shareholders participate in the Share Purchase Plan, on the same terms as the Placement to Platinum, Australian Ethical and other investors,” said Immutep CEO, Marc Voigt. “I would like to thank our shareholders for their continued support, especially those that have been invested in our Company for some time.”
“This funding provides us with cash reach well into Q4 of calendar year 2019, including funding our new Phase II TACTI-002 clinical trial in different cancer indications in collaboration with MSD. Importantly, by that stage we will have Progression Free Survival data from our Phase IIb AIPAC breast cancer trial, data from all four patient cohorts in our Phase I TACTI-mel trial and potentially also the first data from TACTI-002.”
The Company will issue the New Shares today and holding statements will also be sent today to shareholders advising them of the number of New Shares they have been allotted. The New Shares are expected to commence trading on the Australian Securities Exchange on 16 April 2018 and will rank pari passu with the Company's existing fully paid ordinary shares on issue.
For further information please visit www.immutep.com or contact:
U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep
+1 (917) 860-9404; [email protected]
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 (2) 8234 0100; [email protected]
